| Dec'19 | Dec'18 | |||||
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES: | ||||||
Net loss | ||||||
-58,789 | -31,823 | |||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
183 | 253 | |||||
Provision for sales returns | ||||||
134 | 78 | |||||
Amortization of deferred financing costs and debt discounts | ||||||
1,218 | 667 | |||||
Stock-based compensation | ||||||
34,681 | 619 | |||||
Allowance for doubtful accounts | ||||||
35 | - | |||||
Other | ||||||
-59 | -90 | |||||
Loss on early extinguishment on Midcap term loan | ||||||
- | -97 | |||||
Changes in assets and liabilities: | ||||||
Accounts receivable | ||||||
-309 | 70 | |||||
Inventory | ||||||
5,360 | 9,974 | |||||
Prepaid and other current assets | ||||||
1,004 | 1,153 | |||||
Accounts payable, accrued and other liabilities | ||||||
3,334 | 10,871 | |||||
Cash used in operating activities | ||||||
-25,200 | -30,345 | |||||
INVESTING ACTIVITIES: | ||||||
Purchase of fixed assets | ||||||
114 | 61 | |||||
Purchase of Aussie Health Co. assets | ||||||
1,176 | - | |||||
Proceeds on sale of fixed assets | ||||||
6 | 35 | |||||
Cash used in investing activities | ||||||
-1,284 | -26 | |||||
FINANCING ACTIVITIES: | ||||||
Borrowings from Mid Cap credit facility | ||||||
98,663 | 62,665 | |||||
Repayments from Mid Cap credit facility | ||||||
92,165 | 50,784 | |||||
Repayments from Mid Cap term loan | ||||||
- | 6,776 | |||||
Proceeds from exercise of stock options | ||||||
- | 18 | |||||
Proceeds from Initial Public Offering | ||||||
36,000 | - | |||||
Insurance financing proceeds | ||||||
3,833 | - | |||||
Insurance obligation payments | ||||||
2,783 | - | |||||
Capital lease financing proceeds | ||||||
- | 20 | |||||
Capital lease obligation payments | ||||||
55 | 54 | |||||
Prepayment penalty incurred with the Midcap term loan extinguishment | ||||||
- | -97 | |||||
Deferred offering costs | ||||||
- | 947 | |||||
Cash provided by financing activities | ||||||
36,566 | 45,293 | |||||
EFFECT OF EXCHANGE RATE ON CASH | ||||||
-1 | -11 | |||||
NET CHANGE IN CASH AND RESTRICTED CASH FOR PERIOD | ||||||
10,081 | 14,911 | |||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ||||||
Cash paid for interest | ||||||
3,201 | 1,555 | |||||
Cash paid for taxes | ||||||
21 | 3 | |||||
NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||
Equity fundraising costs not paid | ||||||
160 | - | |||||
Debt issuance costs not paid | ||||||
- | 1,388 | |||||
Discount of debt relating to warrants issuance | ||||||
- | 929 | |||||
Capital lease | ||||||
- | 25 | |||||
Note payable on acquisition | ||||||
195 | - | |||||
Mid Cap Credit Facility | ||||||
Debt issuance costs | ||||||
581 | 926 | |||||
Horizon Term Loan | ||||||
Debt issuance costs | ||||||
900 | 215 | |||||
Borrowings from term loan | ||||||
- | 15,000 | |||||
Series C Preferred Stock | ||||||
Proceeds from issuance of preferred stock - converted to common stock | ||||||
- | 23,969 | |||||
Issuance costs of stock | ||||||
- | 2,997 | |||||
Series C-1 Preferred Stock | ||||||
Proceeds from issuance of preferred stock - converted to common stock | ||||||
- | 7,660 | |||||
Issuance costs of stock | ||||||
- | 1,243 | |||||
Initial Public Offering | ||||||
Issuance costs of stock | ||||||
5,446 | - | |||||